Virax Biolabs Group Limited (VRAX) Financials

VRAX Assets vs Liabilities
DateAssetsLiabilities
Sept. 30, 2025 5.7 million 641516
June 30, 2025 6.4 million 964750
March 31, 2025 6.4 million 964750
Sept. 30, 2024 9.4 million 1.0 million

VRAX Free Cash Flow and Stock based compensation
Graph available only for paid members. Upgrade to see it.
DateFree Cash FlowStock based compensation
Sept. 30, 2025 -3.1 million ?
June 30, 2025 -3.0 million 591310
March 31, 2025 -3.0 million 591310
Sept. 30, 2024 -2.2 million 38984

VRAX Net Income

No data available :(

VRAX Cash and Debt
Graph available only for paid members. Upgrade to see it.
DateCashDebtCapital Lease
Sept. 30, 2025 3.3 million - 342416
June 30, 2025 4.2 million - -
March 31, 2025 4.2 million - 344536
Sept. 30, 2024 7.4 million - 380474

VRAX Shares Outstanding
Graph available only for paid members. Upgrade to see it.
DateShares Outstanding
Sept. 30, 2025 4.8 million
June 30, 2025 4.4 million
March 31, 2025 4.3 million
Sept. 30, 2024 3.1 million

VRAX Expenses
Graph available only for paid members. Upgrade to see it.
DateCapexR&DG&AS&M
Sept. 30, 2025 141503 1.4 million 990316 -
June 30, 2025 355895 1.1 million 2.2 million -
March 31, 2025 355895 1.1 million 2.2 million -
Sept. 30, 2024 247995 726412 2.1 million -

VRAX Cost of Revenue
Graph available only for paid members. Upgrade to see it.
DateRevenueCost of Revenue
Sept. 30, 2025 1608 217022
June 30, 2025 1378 47971
March 31, 2025 1378 47971
Sept. 30, 2024 4953 11427

VRAX

Price: $0.17

52 week price:
0.10
1.14

Earnings Per Share: -1.08 USD

Exchange: NCM

Sector: Healthcare

Industry: Biotechnology

Market Capitalization: 1.4 million

Links: